TransCure bioServices contributed to a recent publication by Arianna Moiani and colleagues published in Nature Communication and exploring sickle cell disease (SCD) using CD34+ engrafted humanized mouse models to mimic the human pathology more accurately.
This innovative preclinical approach allows for better evaluation of therapeutic candidates targeting hemoglobin disorders and related complications.
These findings underscore TransCure bioServices’ expertise and commitment to advancing rare disease research through cutting-edge in vivo models.